https://www.biopharmawatch.com/news/GMED/globus-medical-acquisition-higgs-boson-health BiopharmaWatch en 2026-08-26T21:57:00.000Z Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions https://www.biopharmawatch.com/news/IMRX/immuneering-fda-approval-pancreatic-cancer BiopharmaWatch en 2026-08-26T21:16:00.000Z Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients https://www.biopharmawatch.com/news/ALC/alcon-prices-eur-500-million-senior-notes-offering BiopharmaWatch en 2026-08-26T21:00:00.000Z Alcon Prices EUR 500 Million Senior Notes Offering https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-q4-fiscal-year-results BiopharmaWatch en 2026-08-26T20:20:00.000Z Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance https://www.biopharmawatch.com/news/NEO/neogenomics-medicare-coverage-radar-st-assay BiopharmaWatch en 2026-08-26T20:17:00.000Z NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring https://www.biopharmawatch.com/news/BDX/bd-presents-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-26T20:15:00.000Z BD to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-september-investor-conferences BiopharmaWatch en 2026-08-26T20:15:00.000Z First Tracks Biotherapeutics Announces Participation in September Investor Conferences https://www.biopharmawatch.com/news/RXST/rxsight-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T20:15:00.000Z RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2026-results BiopharmaWatch en 2026-08-26T20:05:00.000Z Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/EYE/national-vision-participation-barclays-consumer-conference BiopharmaWatch en 2026-08-26T20:05:00.000Z National Vision, Inc. Announces Participation in Barclays 19th Annual Global Consumer Conference https://www.biopharmawatch.com/news/CNMD/conmed-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T20:05:00.000Z CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T20:05:00.000Z Arcus Biosciences to Participate in Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/GILD/gilead-sciences-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T20:05:00.000Z Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences https://www.biopharmawatch.com/news/XENE/xenon-phase-3-x-tole2-eec-2026 BiopharmaWatch en 2026-08-26T20:01:00.000Z Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 https://www.biopharmawatch.com/news/VRTX/vertex-upcoming-september-investor-conferences BiopharmaWatch en 2026-08-26T20:00:00.000Z Vertex to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/RVMD/fda-approves-revolution-medicines-rasonque-metastatic-pancreatic-cancer BiopharmaWatch en 2026-08-26T16:59:00.000Z U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer https://www.biopharmawatch.com/news/AGEN/agenus-nest-phase-2-publication-colon-cancer BiopharmaWatch en 2026-08-26T14:05:00.000Z Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer https://www.biopharmawatch.com/news/NTHI/neonc-clinical-results-neon100-brain-cancer BiopharmaWatch en 2026-08-26T13:39:00.000Z NeOnc’s Clinical Story Is Now the Main Event https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-presentation-wells-fargo-conference BiopharmaWatch en 2026-08-26T13:15:00.000Z Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/RFL/sofis-appoints-rafael-fraga-ceo BiopharmaWatch en 2026-08-26T13:00:00.000Z Sofis Announces Appointment of Rafael Fraga as CEO https://www.biopharmawatch.com/news/WAT/waters-corporation-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T13:00:00.000Z Waters Corporation to Present at the Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/FEMY/femasys-unc-health-fertility-portfolio BiopharmaWatch en 2026-08-26T13:00:00.000Z Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations https://www.biopharmawatch.com/news/MLSS/milestone-scientific-debt-free-balance-sheet BiopharmaWatch en 2026-08-26T13:00:00.000Z Milestone Scientific Achieves Debt-Free Balance Sheet Through Debt-to-Equity Conversion by Three Directors https://www.biopharmawatch.com/news/DARE/dare-bioscience-sildenafil-cream-menopause-study BiopharmaWatch en 2026-08-26T12:45:00.000Z Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society https://www.biopharmawatch.com/news/ONC/beone-medicines-fda-approval-tevimabra-treatment BiopharmaWatch en 2026-08-26T12:40:00.000Z Riassunto: BeOne Medicines annuncia l'approvazione da parte dell'FDA statunitense del regime a base di TEVIMBRA per il trattamento di prima linea dell'adenocarcinoma gastroesofageo (GEA) HER2-positivo https://www.biopharmawatch.com/news/ONC/beone-medicines-fda-approval-tevimbra-her2-gea BiopharmaWatch en 2026-08-26T12:40:00.000Z Samenvatting: BeOne Medicines kondigt goedkeuring door Amerikaanse FDA aan voor een op TEVIMBRA gebaseerd behandelregime bij eerstelijnsbehandeling van HER2+ GEA https://www.biopharmawatch.com/news/ONC/fda-approval-tevimbra-therapy-her2-positive-gea BiopharmaWatch en 2026-08-26T12:40:00.000Z BeOne Medicines gibt die Zulassung durch die US-amerikanische FDA für eine auf TEVIMBRA basierende Therapie zur Erstlinienbehandlung von HER2-positiver GEA bekannt https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-rural-cardiovascular-care-gap BiopharmaWatch en 2026-08-26T12:35:00.000Z Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-nasdaq-ld-micro-summit BiopharmaWatch en 2026-08-26T12:32:00.000Z Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit https://www.biopharmawatch.com/news/SPRC/scisparc-advances-agentic-ai-strategy-prof-carmel-domshlak BiopharmaWatch en 2026-08-26T12:32:00.000Z SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-september-2026 BiopharmaWatch en 2026-08-26T12:31:00.000Z 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity https://www.biopharmawatch.com/news/ELAN/elanco-expansion-kansas-manufacturing-facility BiopharmaWatch en 2026-08-26T12:30:00.000Z Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility https://www.biopharmawatch.com/news/FBLG/fibrobiologics-regains-nasdaq-compliance BiopharmaWatch en 2026-08-26T12:30:00.000Z FibroBiologics Regains Compliance with Nasdaq Trading Rules https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-phase-3-ovation-3-trial BiopharmaWatch en 2026-08-26T12:30:00.000Z IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-vermont-energy-storage-phase-3 BiopharmaWatch en 2026-08-26T12:30:00.000Z NOMAD Power Solutions, Inc. Receives DOE Authorization to Advance Vermont Long-Duration Energy Storage Project into Phase 3 https://www.biopharmawatch.com/news/CELC/celcuity-submits-snda-fda-revtorpyk-breast-cancer BiopharmaWatch en 2026-08-26T12:30:00.000Z Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer https://www.biopharmawatch.com/news/AMIX/autonomix-medical-us-patent-feedback-guided-therapy BiopharmaWatch en 2026-08-26T12:30:00.000Z Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery https://www.biopharmawatch.com/news/VNRX/volition-clinical-validation-nuq-nets-biomarker-sepsis BiopharmaWatch en 2026-08-26T12:17:00.000Z Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis https://www.biopharmawatch.com/news/HYPR/hyperfine-neurology-office-launch-momentum BiopharmaWatch en 2026-08-26T12:15:00.000Z Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans https://www.biopharmawatch.com/news/CADL/candel-therapeutics-september-investor-conferences BiopharmaWatch en 2026-08-26T12:05:00.000Z Candel Therapeutics to Present at September Investor Conferences https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-launch-mps3bstudy-com BiopharmaWatch en 2026-08-26T12:00:00.000Z Spruce Biosciences Announces Launch of MPS3BStudy.com https://www.biopharmawatch.com/news/OABI/omniab-participate-investor-conferences BiopharmaWatch en 2026-08-26T12:00:00.000Z OmniAb to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T12:00:00.000Z Odyssey Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-esc-congress-2026-presentations BiopharmaWatch en 2026-08-26T12:00:00.000Z NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/INNV/innovage-conference-call-fiscal-2026-results BiopharmaWatch en 2026-08-26T12:00:00.000Z InnovAge Announces Conference Call to Discuss Fourth Quarter and Fiscal 2026 Financial Results and Participation in Upcoming Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T12:00:00.000Z Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/XERS/xeris-xp-8121-webinar-details BiopharmaWatch en 2026-08-26T11:30:00.000Z Xeris Announces Details for XP-8121 Program Overview Webinar https://www.biopharmawatch.com/news/RGEN/repligen-corporation-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T11:30:00.000Z Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-ers-congress-2026-presentations BiopharmaWatch en 2026-08-26T11:30:00.000Z Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T11:30:00.000Z Eikon Therapeutics to Participate in Investor Conferences in September 2026 https://www.biopharmawatch.com/news/PODD/insulet-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T11:00:00.000Z Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-private-offering-exchangeable-notes BiopharmaWatch en 2026-08-26T11:00:00.000Z Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases https://www.biopharmawatch.com/news/INSM/insmed-september-2026-investor-conferences BiopharmaWatch en 2026-08-26T11:00:00.000Z Insmed to Present at September 2026 Investor Conferences https://www.biopharmawatch.com/news/INMB/inmune-bio-ebstrocel-eu-marketing-authorization BiopharmaWatch en 2026-08-26T11:00:00.000Z INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-doses-first-patient-phase-1-2a-trial BiopharmaWatch en 2026-08-26T11:00:00.000Z Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors https://www.biopharmawatch.com/news/KMTS/kestra-appoints-curtis-kopf-svp-customer-experience BiopharmaWatch en 2026-08-26T10:00:00.000Z Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience https://www.biopharmawatch.com/news/NBIX/neurocrine-fda-phase-2-nbi-1117567-alzheimers BiopharmaWatch en 2026-08-26T07:33:00.000Z Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition https://www.biopharmawatch.com/news/BHVN/biohaven-sk-biopharmaceuticals-licensing-agreement-opakalim BiopharmaWatch en 2026-08-26T06:36:00.000Z Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy https://www.biopharmawatch.com/news/YDES/yd-bio-research-publication-nutrients BiopharmaWatch en 2026-08-26T02:51:20.000Z YD Bio 宣布與台灣慢性病照護協會及未來健康研究院醫師共同撰寫的同行評審文章在 Nutrients 期刊正式發表 https://www.biopharmawatch.com/news/CELU/celularity-nasdaq-listing-compliance-update BiopharmaWatch en 2026-08-25T23:59:00.000Z Celularity Provides Update Regarding Nasdaq Listing Compliance https://www.biopharmawatch.com/news/BIIB/biogen-selects-veeva-vault-crm BiopharmaWatch en 2026-08-25T23:35:00.000Z Biogen entscheidet sich für Veeva Vault CRM https://www.biopharmawatch.com/news/SCYX/scynexis-inducement-award-nasdaq-rule-5635 BiopharmaWatch en 2026-08-25T23:06:00.000Z SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SMMT/ivonescimab-chemotherapy-survival-benefit-biliary-cancer BiopharmaWatch en 2026-08-25T22:00:00.000Z Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China https://www.biopharmawatch.com/news/UHS/universal-health-services-september-conferences BiopharmaWatch en 2026-08-25T21:15:00.000Z UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT SEPTEMBER HEALTHCARE CONFERENCES https://www.biopharmawatch.com/news/BHVN/biohaven-yale-trade-secret-case-judgment BiopharmaWatch en 2026-08-25T20:41:00.000Z Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-first-quarter-results-2027 BiopharmaWatch en 2026-08-25T20:14:00.000Z Kewaunee Scientific to Report Results for First Quarter Fiscal Year 2027 https://www.biopharmawatch.com/news/BIIB/biogen-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-25T20:06:00.000Z Biogen to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/ELMD/electromed-ceo-planned-retirement BiopharmaWatch en 2026-08-25T20:05:00.000Z Electromed Announces CEO’s Planned Retirement https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-presentation-morgan-stanley-2026 BiopharmaWatch en 2026-08-25T20:05:00.000Z Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/ELMD/electromed-record-fiscal-2026-results BiopharmaWatch en 2026-08-25T20:05:00.000Z Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-inducement-grant-nasdaq-rule-5635 BiopharmaWatch en 2026-08-25T20:05:00.000Z Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NNOX/nanox-report-q2-2026-financial-results BiopharmaWatch en 2026-08-25T20:05:00.000Z Nanox to Report Second Quarter 2026 Financial Results on September 9, 2026 https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-skyway-phase-2-trial-results BiopharmaWatch en 2026-08-25T20:01:00.000Z Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 https://www.biopharmawatch.com/news/ASND/ascendis-transcon-cnp-isds-2026-presentation BiopharmaWatch en 2026-08-25T20:01:00.000Z Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 https://www.biopharmawatch.com/news/PEN/incuvate-files-patent-infringement-lawsuit-against-penumbra BiopharmaWatch en 2026-08-25T19:28:00.000Z Incuvate Files Patent Infringement Lawsuit Against Penumbra https://www.biopharmawatch.com/news/IGC/alzheimers-global-patterns-regional-disparities BiopharmaWatch en 2026-08-25T15:29:10.000Z Alzheimer’s Across Borders: A Global look at regional patterns and drivers of Alzheimer’s Disease https://www.biopharmawatch.com/news/ONC/beone-medicines-fda-approval-tevimbra-her2-gea BiopharmaWatch en 2026-08-25T14:40:00.000Z BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA https://www.biopharmawatch.com/news/ZYME/fda-approves-ziihera-advanced-gea BiopharmaWatch en 2026-08-25T14:23:00.000Z U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma https://www.biopharmawatch.com/news/BIIB/biogen-selects-veeva-vault-crm-global-platform BiopharmaWatch en 2026-08-25T13:39:00.000Z Veeva Vault CRM seleccionado por Biogen https://www.biopharmawatch.com/news/DGX/quest-diagnostics-baird-2026-global-healthcare-conference BiopharmaWatch en 2026-08-25T13:30:00.000Z Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference https://www.biopharmawatch.com/news/MCK/ai-enterprise-demand-investor-confidence-pharma-tech BiopharmaWatch en 2026-08-25T13:15:00.000Z Investors and Entrepreneurs Agree: AI, Enterprise Demand and Investor Confidence Are Reshaping Pharma Tech, According to New McKesson Ventures Report https://www.biopharmawatch.com/news/MMED/minimed-participate-upcoming-investor-conferences BiopharmaWatch en 2026-08-25T13:03:00.000Z MiniMed to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CVS/cvs-home-team-heroes-contest-youth-soccer BiopharmaWatch en 2026-08-25T13:00:00.000Z CVS Pharmacy® launches Home Team Heroes contest to celebrate youth soccer players https://www.biopharmawatch.com/news/HCWB/hcw-biologics-tgf-beta-il-15-fusion-immunotherapy BiopharmaWatch en 2026-08-25T13:00:00.000Z HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells https://www.biopharmawatch.com/news/GMAB/genmab-participate-investor-conferences-september-2026 BiopharmaWatch en 2026-08-25T13:00:00.000Z Genmab to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/RMD/tyler-reddick-sleep-apnea-resmed-collaboration BiopharmaWatch en 2026-08-25T13:00:00.000Z 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs https://www.biopharmawatch.com/news/DARE/dare-bioscience-ceo-commercial-transformation-pipeline BiopharmaWatch en 2026-08-25T12:55:00.000Z Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-new-patient-referrals-nevada BiopharmaWatch en 2026-08-25T12:45:00.000Z Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers https://www.biopharmawatch.com/news/NKTR/nektar-rezolve-ad-phase-2b-results BiopharmaWatch en 2026-08-25T12:30:00.000Z Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis https://www.biopharmawatch.com/news/DRMA/dermata-launches-tome-foundational-treatment BiopharmaWatch en 2026-08-25T12:30:00.000Z Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-soteria-phase-2-trial-update BiopharmaWatch en 2026-08-25T12:30:00.000Z Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial https://www.biopharmawatch.com/news/RNXT/renovorx-pk-pd-data-tamp-targeted-drug-delivery BiopharmaWatch en 2026-08-25T12:30:00.000Z RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/SEPN/septerna-appoints-rajiv-patni-cmo BiopharmaWatch en 2026-08-25T12:00:17.000Z Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/ATRC/atricure-participate-2026-wells-fargo-health-care-conference BiopharmaWatch en 2026-08-25T12:00:00.000Z AtriCure to Participate in the 2026 Wells Fargo Health Care Conference https://www.biopharmawatch.com/news/MCK/mckesson-acquires-precision-medicine-group BiopharmaWatch en 2026-08-25T12:00:00.000Z McKesson Signs Agreement to Acquire Precision Medicine Group, LLC https://www.biopharmawatch.com/news/ANVS/annovis-corporate-update-webinar-september-2026 BiopharmaWatch en 2026-08-25T12:00:00.000Z Annovis to Host Corporate Update Webinar on September 2, 2026 https://www.biopharmawatch.com/news/YDES/yd-bio-peer-reviewed-publication-nutrients BiopharmaWatch en 2026-08-25T12:00:00.000Z YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute https://www.biopharmawatch.com/news/CVRX/cvrx-responds-pointillist-family-office-letter BiopharmaWatch en 2026-08-25T12:00:00.000Z CVRx Responds to Letter from Pointillist Family Office https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-q3-2026-financial-results-update BiopharmaWatch en 2026-08-25T12:00:00.000Z Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/ECOR/truvaga-best-luxury-biohacking-brand-2026 BiopharmaWatch en 2026-08-25T12:00:00.000Z electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards https://www.biopharmawatch.com/news/HIND/vyome-holdings-q2-2026-results-vt-1953-advancement BiopharmaWatch en 2026-08-25T12:00:00.000Z Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-miplyffa-npc-ssieme-symposium-2026 BiopharmaWatch en 2026-08-25T11:30:00.000Z Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium https://www.biopharmawatch.com/news/BIIB/biogen-adopts-veeva-vault-crm-global-partnership BiopharmaWatch en 2026-08-25T11:17:00.000Z Biogen a choisi Veeva Vault CRM https://www.biopharmawatch.com/news/KIDS/orthopediatrics-launch-3p-pediatric-plating-platform-hip-system BiopharmaWatch en 2026-08-25T11:05:00.000Z OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations https://www.biopharmawatch.com/news/RGNX/regenxbio-appoints-greg-ciongoli-board-directors BiopharmaWatch en 2026-08-25T11:05:00.000Z REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli https://www.biopharmawatch.com/news/BIIB/biogen-selects-veeva-vault-crm-global-partnership BiopharmaWatch en 2026-08-25T11:03:00.000Z Veeva Vault CRM Selected by Biogen https://www.biopharmawatch.com/news/OCGN/ocugen-participate-september-investor-conferences BiopharmaWatch en 2026-08-25T11:02:00.000Z Ocugen to Participate in Upcoming September Investor and Industry Conferences https://www.biopharmawatch.com/news/SMMT/ivonescimab-phase-iii-harmoni-results-lancet-oncology BiopharmaWatch en 2026-08-25T11:00:00.000Z Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology https://www.biopharmawatch.com/news/BLRX/biolinerx-report-q2-2026-results-conference-call BiopharmaWatch en 2026-08-25T11:00:00.000Z BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 https://www.biopharmawatch.com/news/XAIR/beyond-air-sells-neuronos-stake-to-univo BiopharmaWatch en 2026-08-25T11:00:00.000Z Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-appoints-dr-craig-tendler BiopharmaWatch en 2026-08-25T11:00:00.000Z Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors https://www.biopharmawatch.com/news/GANX/gain-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-25T11:00:00.000Z Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IMTX/immatics-announces-150-million-offering BiopharmaWatch en 2026-08-25T11:00:00.000Z Immatics Announces $150 Million Underwritten Offering https://www.biopharmawatch.com/news/AVAH/aveanna-participate-jefferies-healthcare-conference-2026 BiopharmaWatch en 2026-08-25T11:00:00.000Z Aveanna to Participate in the 2026 Jefferies Healthcare Services and Technology Conference https://www.biopharmawatch.com/news/SGMT/sagimet-advances-aurora-phase-3-trial-denifanstat-acne BiopharmaWatch en 2026-08-25T11:00:00.000Z Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 https://www.biopharmawatch.com/news/NUTX/fifth-circuit-rejects-ghost-rates-nutex-health BiopharmaWatch en 2026-08-25T09:30:00.000Z Fifth Circuit Rejects "Ghost Rates" in Federal QPA Calculations Under the No Surprises Act https://www.biopharmawatch.com/news/MOLN/molecular-partners-h1-2026-results-mp0712-trial-update BiopharmaWatch en 2026-08-25T05:00:48.000Z Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study https://www.biopharmawatch.com/news/AMIX/autonomix-medical-warrant-inducement-agreement BiopharmaWatch en 2026-08-25T01:06:00.000Z Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules https://www.biopharmawatch.com/news/JAZZ/fda-approves-ziihera-first-line-her2-advanced-gea BiopharmaWatch en 2026-08-25T00:00:00.000Z U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera®...